Anagrelide

Anagrelide
Clinical data
Trade names	Agrylin
AHFS/Drugs.com	Monograph
MedlinePlus	a601020
Pregnancy; category	AU: B3;
Routes of; administration	By mouth
ATC code	L01XX35 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Metabolism	Liver, partially through CYP1A2
Elimination half-life	1.3 hours
Excretion	Urine (<1%)
Identifiers
	IUPAC name 6,7-dichloro-1,5-dihydroimidazo; (2,1-b)quinazolin-2(3H)-one;
CAS Number	68475-42-3 ;
PubChem CID	2182;
IUPHAR/BPS	7114;
DrugBank	DB00261 ;
ChemSpider	2097 ;
UNII	K9X45X0051;
KEGG	D07455 ;
ChEBI	CHEBI:142290 ;
ChEMBL	ChEMBL760 ;
CompTox Dashboard (EPA)	DTXSID4048305 ;
ECHA InfoCard	100.317.113
Chemical and physical data
Formula	C10H7Cl2N3O
Molar mass	256.09 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1NC2=Nc3c(CN2C1)c(Cl)c(cc3)Cl;
	InChI InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16) ; Key:OTBXOEAOVRKTNQ-UHFFFAOYSA-N ;
	(verify)

Anagrelide (Agrylin/Xagrid, Shire and Thromboreductin, AOP Orphan Pharmaceuticals AG) is a drug used for the treatment of essential thrombocytosis (also known as essential thrombocythemia), or overproduction of blood platelets. It also has been used in the treatment of chronic myeloid leukemia.^[2]

Anagrelide controlled release (GALE-401) is in phase III clinical trials by Galena Biopharma for the treatment of essential thrombocytosis.^[3]

^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
^ Voglová J, Maisnar V, Beránek M, Chrobák L (2006). "[Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase]". Vnitr̆ní Lékar̆ství (in Czech). 52 (9): 819–22. PMID 17091608.
^ "Galena Biopharma Confirms Regulatory Pathway for GALE-401 (Anagrelide Controlled Release)". Galena Biopharma, Inc. (Press release). 2016-12-28 – via globenewswire.com.

[1] "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.

[pmid17091608-2] Voglová J, Maisnar V, Beránek M, Chrobák L (2006). "[Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase]". Vnitr̆ní Lékar̆ství (in Czech). 52 (9): 819–22. PMID 17091608.

[3] "Galena Biopharma Confirms Regulatory Pathway for GALE-401 (Anagrelide Controlled Release)". Galena Biopharma, Inc. (Press release). 2016-12-28 – via globenewswire.com.

[1]

[2]

[3]